Such protocols should be based on the circadian rhythm for any new anti-GBM drug or adjuvant (e.g., REV-ERB and CRY agonists, melatonin or curcumin, together with, or as a substitute to already approved TMZ), and the patient's circadian clock during the clinical treatment to improve the disease prognosis. This evidence concerns the gene CRYL1 and glioblastoma.